Class Actions · Mass Torts · Securities FraudCall (918) 238-6445
Menu

Active Cases

Pending securities class actions with reported lead plaintiff deadlines, and mass tort litigation in which new claims are being filed.

Case Evaluation

Cases filed by the firm

Matters in which Schwartz & Associates, PC is counsel of record. Descriptions summarize allegations in court filings; allegations are not findings, and prior results do not guarantee a similar outcome.

Firm case

LaChance v. TruGolf Holdings, Inc., et al.

NASDAQ: TRUG · D. Utah · 1:26-cv-00119-JNP-CMR · filed July 24, 2026

The complaint alleges that defendants misrepresented or failed to disclose that holders of TruGolf's Series A Convertible Preferred Stock were continuously converting into Class A shares at floating and ratcheting conversion prices, causing substantial ongoing dilution, and that TruGolf's April 15, 2026 Form 10-K overstated its outstanding Class A shares by 480,504 shares, or approximately 52%. The complaint alleges that the financing and related misstatements contributed to a decline of more than 98% in the split-adjusted price of TruGolf's Class A common stock.

Class period
September 10, 2025 to May 20, 2026
Reported lead plaintiff deadline
September 28, 2026
Claims
Securities Act Sections 11 and 15; Exchange Act Sections 10(b), 14(a) and 20(a); related shareholder derivative claims
The firm's role
Schwartz & Associates, PC is counsel of record for the plaintiff in this action, the first-filed securities class action concerning TruGolf.
Case detailsTalk to the firm about this case

Public records

Pending cases

Pending securities class actions with reported lead plaintiff deadlines, and mass tort litigation still open to new filings. Compiled as of September 11, 2026.

Unless marked Firm case, the firm is not counsel in these cases. Descriptions of filed cases summarize allegations in court complaints; allegations are not findings. Verdicts and settlements in other people's cases do not predict the outcome or value of any other claim. Deadlines are compiled from public notices and dockets and are not verified against the statutory notice; confirm any date on the court docket before relying on it.

What a lead plaintiff deadline means. It applies only to an investor who wants to ask the court to appoint them lead plaintiff, and it runs 60 days from publication of the statutory notice under 15 U.S.C. §§ 77z-1(a)(3) and 78u-4(a)(3). You do not need to do anything by that date to remain a member of any class that may be certified. Three things matter later: to receive money from a settlement you will ordinarily need to submit a claim form by a deadline; if you do not exclude yourself by the deadline in the court's notice, you are bound by the result; and statutory time limits may run regardless of the class action, so anyone considering an individual case should get advice promptly.

Securities class actions

Company and allegationsClass periodReported lead plaintiff deadlineCourt and docketAsk
Planet Fitness, Inc. NYSE: PLNT
The complaint alleges Planet Fitness made misleading statements about its marketing strategy, membership growth and a planned Black Card price increase; on May 7, 2026 it cut guidance, withdrew its growth algorithm and paused the increase.
 November 6, 2025 to May 6, 2026 September 14, 2026
 D.N.H.
1:26-cv-00576		 Ask about this
Regeneron Pharmaceuticals, Inc. NASDAQ: REGN
The complaint alleges Regeneron misrepresented the status of its Phase III fianlimab-Libtayo melanoma trial, characterizing slow event accrual as a sign of efficacy while not disclosing increased risk of failure and flawed statistical assumptions.
 August 1, 2025 to May 15, 2026 September 14, 2026
 S.D.N.Y.
7:26-cv-06026		 Ask about this
GPGI, Inc. NYSE: GPGI
The complaint alleges GPGI (formerly CompoSecure), executives and its external manager overstated the value of the Husky Technologies acquisition and that proxy targets lacked a reasonable basis.
 November 3, 2025 to May 6, 2026 September 14, 2026 or September 15, 2026
Notices conflict: the filing firm's notice states September 14, 2026; other notices state September 15, 2026.
 S.D.N.Y.
1:26-cv-05951		 Ask about this
Cogent Communications Holdings, Inc. NASDAQ: CCOI
The complaint alleges Cogent misrepresented demand for optical wavelength services and its order backlog, and that revenue and margin targets lacked a reasonable basis; it later cut its dividend by 98%.
 February 29, 2024 to May 1, 2026 September 21, 2026
 D.D.C.
1:26-cv-02609		 Ask about this
EquipmentShare.com Inc. NASDAQ: EQPT
The complaint alleges the January 2026 IPO documents failed to disclose related-party transactions through which founding-family entities received tens of millions of dollars; it cites a June 24, 2026 short-seller report.
Who may be affected: Investors who purchased EquipmentShare Class A common stock pursuant or traceable to the January 2026 IPO registration statement, or between January 23, 2026 and June 23, 2026.
 January 23, 2026 to June 23, 2026 September 21, 2026
 S.D.N.Y.
1:26-cv-06288		 Ask about this
Microvast Holdings, Inc. NASDAQ: MVST
The complaint alleges Microvast overstated its ability to meet margin targets and the progress of its Huzhou expansion while not disclosing inventory problems and customer rollout delays.
 April 1, 2025 to March 16, 2026 September 21, 2026
 S.D. Tex.
4:26-cv-05804		 Ask about this
Primoris Services Corporation NYSE: PRIM
The complaint alleges Primoris misrepresented its bidding discipline and project controls for fixed-price renewable energy projects, culminating in disclosed cost overruns on six projects and reduced guidance.
 August 5, 2025 to June 22, 2026 September 21, 2026
 N.D. Tex.
3:26-cv-02416		 Ask about this
Park Ha Biological Technology Co., Ltd. NASDAQ: BYAH
The complaint alleges that Park Ha (formerly traded as PHH) was the subject of a pump-and-dump scheme in which impersonators using stolen identities of financial advisors promoted its shares with false claims, and that its IPO was deliberately structured with an extremely low public float to enable the manipulation. The complaint alleges that on July 8, 2025 the share price fell approximately 93% in a single trading session.
Who may be affected: Includes Securities Act claims tied to the December 2024 IPO; defendants include auditor WWC, P.C., IPO underwriters Dawson James Securities, Inc. and D. Boral Capital LLC, and Xiaoqiu Holding Ltd., in addition to the issuer and individuals.
 December 27, 2024 to July 8, 2025 September 21, 2026 or September 28, 2026
Most notices state September 28, 2026; one notice states September 21, 2026.
 S.D.N.Y.
1:26-cv-06421		 Ask about this
Hertz Global Holdings, Inc. NASDAQ: HTZ
The complaint alleges Hertz misled investors about fleet discipline, depreciation, residual vehicle values and liquidity while omitting deteriorating used-car market conditions; a June 24, 2026 notes offering and results warning followed.
 May 7, 2026 to June 23, 2026 September 22, 2026
 M.D. Fla.
2:26-cv-02242		 Ask about this
PROCEPT BioRobotics Corporation NASDAQ: PRCT
The complaint alleges PROCEPT presented handpiece sales as a proxy for procedure volume while sales exceeded procedures, creating excess field inventory driven in part by an undisclosed end-of-quarter discount program.
 February 28, 2024 to February 25, 2026 September 22, 2026
 N.D. Cal.
5:26-cv-07691		 Ask about this
Wix.com Ltd. NASDAQ: WIX
The complaint alleges Wix overstated the competitiveness and performance of its AI products while understating development costs; it reported disappointing results on May 13, 2026.
 February 19, 2025 to May 12, 2026 September 22, 2026
 N.D. Ill.
1:26-cv-08852		 Ask about this
Capricor Therapeutics, Inc. NASDAQ: CAPR
The complaint alleges Capricor concealed facts about the regulatory pathway for deramiocel, including revising its statistical analysis plan without FDA agreement shortly before data unblinding.
 December 17, 2025 to July 26, 2026 September 28, 2026
 S.D. Cal.
3:26-cv-04385		 Ask about this
Rackspace Technology, Inc. NASDAQ: RXT
The complaint alleges Rackspace failed to disclose that its enterprise AI initiatives would shift capacity and capital away from its Private Cloud segment and concealed declines in Public Cloud revenue; guidance was cut on July 9, 2026.
 May 7, 2026 to July 8, 2026 September 28, 2026
 S.D.N.Y.
1:26-cv-06491		 Ask about this
Bloom Energy Corporation NYSE: BE
The complaint alleges that defendants made false or misleading statements about Bloom Energy's scandium supply chain, including that the company obtained scandium through intermediaries who sourced the metal from China and understated the extent of its reliance on Chinese scandium. The complaint alleges that after Hunterbrook Media published a report titled "Bloom's Big Lie" on July 8, 2026, Bloom's stock fell $15.28, or 5.7%, to close at $254.29 per share.
 February 27, 2025 to July 8, 2026 September 28, 2026
 N.D. Cal.
3:26-cv-07944		 Ask about this
TruGolf Holdings, Inc. NASDAQ: TRUGFirm case
The complaint alleges that defendants misrepresented or failed to disclose that holders of TruGolf's Series A Convertible Preferred Stock were continuously converting into Class A shares at floating and ratcheting conversion prices, causing substantial ongoing dilution, and that TruGolf's April 15, 2026 Form 10-K overstated its outstanding Class A shares by 480,504 shares, or approximately 52%. The complaint alleges that the financing and related misstatements contributed to a decline of more than 98% in the split-adjusted price of TruGolf's Class A common stock.
Who may be affected: Investors who purchased or otherwise acquired TruGolf Class A common stock during the class period.
 September 10, 2025 to May 20, 2026 September 28, 2026
 D. Utah
1:26-cv-00119-JNP-CMR		 Ask about this
iTonic Holdings Ltd NASDAQ: ITOC
The complaint alleges iTonic (formerly Pheton Holdings) and related defendants failed to disclose involvement in a scheme to manipulate its stock through social media misinformation and impersonators posing as financial professionals.
 September 5, 2024 to July 29, 2025 September 29, 2026
 S.D.N.Y.
1:26-cv-06484		 Ask about this
Avis Budget Group, Inc. NASDAQ: CAR
Brought on behalf of Avis investors against Pentwater Capital Management LP and its founder, not against Avis. The complaint alleges a scheme to manipulate the market for Avis securities that produced a short squeeze.
Who may be affected: Investors who purchased or otherwise acquired Avis Budget Group securities between February 20, 2025 and April 21, 2026. Defendants are an investment manager and its principal, not the company.
 February 20, 2025 to April 21, 2026 September 29, 2026
 M.D. Fla.
2:26-cv-02275		 Ask about this
Wise Group plc NASDAQ: WSE
The complaint alleges Wise understated regulatory risks tied to allegedly deficient anti-money-laundering and counter-terrorism-financing controls in connection with its U.S. listing.
 May 11, 2026 to July 23, 2026 September 29, 2026
 S.D.N.Y.
1:26-cv-06582		 Ask about this
DNOW Inc. NYSE: DNOW
The complaint alleges DNOW made misleading statements in connection with the shareholder vote on its merger with MRC Global, negligently understating problems with MRC Global's ERP system.
Who may be affected: Holders of DNOW common stock as of the August 5, 2025 record date entitled to vote at the September 9, 2025 special meeting on the MRC Global merger.
 See case description October 2, 2026
 S.D. Tex.
4:26-cv-06261		 Ask about this
Pentair plc NYSE: PNR
The complaint alleges Pentair failed to disclose substantial inventory destocking in its Pool segment; on July 14, 2026 it announced sales below guidance, cut full-year guidance and disclosed its CFO's departure.
 April 28, 2026 to July 14, 2026 October 2, 2026
 S.D.N.Y.
1:26-cv-06632		 Ask about this
Alarum Technologies Ltd. NASDAQ: ALAR
The complaint alleges Alarum made misleading statements about its NetNut subsidiary, including that it routed traffic through consumers' home devices without consent, exposing the company to legal and business risk.
 March 20, 2025 to July 2, 2026 October 5, 2026
 D.N.J.
2:26-cv-09884		 Ask about this
Alibaba Group Holding Limited NYSE: BABA
The complaint alleges Alibaba's risk disclosures were misleading about potential designation as a Chinese military company and about ongoing distillation attacks against third-party AI models.
 June 26, 2025 to June 24, 2026 October 5, 2026
 S.D.N.Y.
1:26-cv-06654		 Ask about this
ARS Pharmaceuticals, Inc. NASDAQ: SPRY
The complaint alleges ARS made positive statements about expanding insurance coverage for its neffy nasal spray while concealing that a major PBM coverage decision had been pushed to January 2027.
 March 9, 2026 to June 24, 2026 October 5, 2026
 S.D. Cal.
3:26-cv-04469		 Ask about this
Blaize Holdings, Inc. NASDAQ: BZAI
The complaint alleges Blaize announced transactions with counterparties lacking capacity for meaningful business, creating a misleading appearance of commercial traction, and improperly recognized revenue.
 July 18, 2025 to April 28, 2026 October 5, 2026
 C.D. Cal.
2:26-cv-08563		 Ask about this
Datavault AI Inc. NASDAQ: DVLT
The complaint alleges Datavault overstated the value of announced partnerships and activity on its platform and failed to disclose ties to an individual with a felony conviction, following an October 31, 2025 short-seller report.
 September 4, 2024 to October 30, 2025 October 5, 2026
 E.D. Pa.
2:26-cv-05548		 Ask about this
Replimune Group, Inc. NASDAQ: REPL
The complaint alleges Replimune made misleading statements about its resubmitted BLA for RP1, which allegedly did not resolve FDA study-design concerns and relied on an early unplanned analysis of limited data.
 October 20, 2025 to April 10, 2026 October 5, 2026
 D. Mass.
1:26-cv-13612		 Ask about this
Smartsheet, Inc. NYSE: SMAR
The complaint alleges Smartsheet repurchased its own shares while failing to disclose credible private-equity acquisition offers at a higher price; it announced a $56.50 per share merger on September 24, 2024.
Who may be affected: Investors who SOLD Smartsheet common stock between June 1, 2024 and September 23, 2024 (a seller class, not purchasers).
 June 1, 2024 to September 23, 2024 October 5, 2026
 S.D.N.Y.
1:26-cv-06679		 Ask about this
Aardvark Therapeutics, Inc. NASDAQ: AARD
The complaint alleges that defendants made false or misleading statements and failed to disclose adverse information about the safety of lead candidate ARD-101, including reversible cardiac observations at above-target doses, and overstated its clinical, regulatory and commercial prospects. The complaint alleges that after Aardvark announced a voluntary pause of its Phase 3 HERO trial on February 27, 2026, the stock fell $7.02, or 56.2%, to $5.47 on March 2, 2026, and after the FDA placed a full clinical hold on ARD-101 on May 14, 2026, it fell $2.16, or 32.1%, to $4.57 on May 15, 2026.
Who may be affected: IPO tracing: class includes purchasers of common stock pursuant or traceable to the offering documents for the February 13, 2025 IPO, in addition to purchasers of securities from February 13, 2025 to May 14, 2026.
 February 13, 2025 to May 14, 2026 October 13, 2026
 S.D. Cal.
3:26-cv-04643		 Ask about this
HDFC Bank Limited NYSE: HDB
The complaint alleges that HDFC failed to disclose that it camouflaged payments as marketing spend in order to pay higher interest to a state entity, the Maharashtra State Road Development Corporation (roughly Rs 45 crore, about $4.7 million), conduct allegedly contrary to regulations and company policies. The complaint alleges that the stock fell $2.09, or 7.28%, to $26.62 after the March 18, 2026 resignation of Chairman Atanu Chakraborty, and fell $1.02, or 4.11%, to $23.78 after a May 27, 2026 news report on the payments.
 July 17, 2023 to May 26, 2026 October 13, 2026
 S.D.N.Y.
1:26-cv-06943		 Ask about this
The Simply Good Foods Company NASDAQ: SMPL
The complaint alleges that defendants concealed problems with the integration of the OWYN acquisition, including loss of key personnel, quality problems with pea-protein formulations, margin erosion from discounting and reduced brand support. The complaint alleges that the stock fell more than 17% on October 23, 2025, when the company disclosed a quality issue with the OWYN brand, and fell more than 27% over two trading days after its April 9, 2026 second-quarter results, which included a $249.0 million non-cash impairment charge related to the Atkins and OWYN brands.
 October 24, 2024 to April 8, 2026 October 13, 2026
 S.D.N.Y.
1:26-cv-06971		 Ask about this
UWM Holdings Corporation NYSE: UWMC
The complaint alleges that UWM failed to disclose that it had deviated from its traditional strategy of not hedging its mortgage servicing rights to take a major hedge position, and had over-hedged in anticipation of the Two Harbors Investment Corp. transaction. The complaint alleges that on August 5, 2026 UWM reported a $603.2 million interest rate derivatives loss and a $451.9 million second-quarter net loss, and that after the CEO disclosed the over-hedging on August 6, 2026 the stock fell $0.64, or 34.78%, to close at $1.20 per share.
 March 9, 2026 to August 5, 2026 October 13, 2026
 E.D. Mich.
2:26-cv-12862		 Ask about this
AEVEX Corp. NYSE: AVEX
The complaint alleges that defendants concealed a pre-arranged plan among Madison Dearborn Partners, LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC to prematurely abrogate the 180-day lock-up that followed AEVEX's April 2026 IPO. The complaint alleges that the stock fell approximately 16% after AEVEX announced an 8 million share secondary offering on June 1, 2026, and fell a further 7% after the June 5, 2026 secondary-offering prospectus disclosed the lock-up waiver.
Who may be affected: IPO tracing: class includes purchasers of Class A common stock pursuant or traceable to the April 2026 IPO registration statement and prospectus, plus purchasers of publicly traded Class A common stock April 17 to June 4, 2026. Defendants other than the issuer include controlling owner Madison Dearborn Partners, LLC and IPO underwriters Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC.
 April 17, 2026 to June 4, 2026 October 20, 2026
 S.D. Cal.
3:26-cv-04779		 Ask about this
GoDaddy Inc. NYSE: GDDY
The complaint alleges that GoDaddy concealed a promotional discount strategy for dotcom domains that shortened contract terms, contrary to prior statements that it had turned off discounts and was prioritizing larger order sizes. The complaint alleges that when GoDaddy reported fourth-quarter 2025 results on February 24, 2026 showing total bookings growth had decelerated to 5%, the stock fell more than 14%.
 September 3, 2025 to February 24, 2026 October 20, 2026
 S.D.N.Y.
1:26-cv-07144		 Ask about this
Fractyl Health, Inc. NASDAQ: GUTS
The complaint alleges that defendants made false or misleading statements about the effectiveness of the Revita DMR System. The complaint alleges that on January 29, 2026 Fractyl released six-month REMAIN-1 Midpoint Cohort data showing 4.5% weight regain versus 7.5% in the sham arm, and the stock fell $1.245 per share, or 68.03%, then fell a further $0.125, or 21.37%, after analyst downgrades.
 January 13, 2025 to January 29, 2026 October 20, 2026
 S.D.N.Y.
1:26-cv-07167		 Ask about this
Taboola.com Ltd. NASDAQ: TBLA
The complaint alleges that defendants failed to disclose that Taboola was seeing an increase in low-quality publishers, that it would need to take an aggressive approach to exiting those relationships, affecting earnings, and that the value of its publisher relationships was overstated. The complaint alleges that on August 5, 2026 Taboola reported second-quarter revenue below its prior guidance and lowered its full-year outlook, and the stock fell $1.45, or 27.41%, to close at $3.84.
 May 6, 2026 to August 4, 2026 October 20, 2026
 S.D.N.Y.
1:26-cv-07170		 Ask about this
Flotek Industries, Inc. NYSE: FTK
The complaint alleges that, after Flotek announced on August 3, 2026 a $400 million revenue backlog tied to a Puerto Rico Electric Power Authority (PREPA) power generation contract, defendants failed to disclose doubts about the experience, organization and financial capacity of the consortium parties and the risk that the contract revenue would not materialize. The complaint alleges that the stock fell $7.17, or 20.01%, to $28.66 after an August 17, 2026 Wolfpack Research report said the contract had been cancelled, and fell a further $1.64, or 5.72%, to $27.02 after PREPA directed termination of Flotek's contract on August 18, 2026.
 August 3, 2026 to August 17, 2026 October 26, 2026
 S.D.N.Y.
1:26-cv-07285		 Ask about this
York Space Systems Inc. NYSE: YSS
The complaint alleges that the offering documents for York Space's January 2026 IPO (approximately 18.5 million shares at $34.00 per share) and later statements failed to disclose that onboard mission and payload software was not fully functional before satellites were launched, putting its Space Development Agency contracts at risk. The complaint alleges that on May 11, 2026 Wolfpack Research published a report titled "YSS: Lost In Space - The Pentagon Just Killed 96% of York's Revenue."
Who may be affected: IPO tracing: class includes purchasers of common stock pursuant or traceable to the January 2026 IPO registration statement, plus purchasers of securities January 29 to May 11, 2026. Defendants other than the issuer include incoming directors and IPO underwriters (Goldman Sachs & Co. LLC, Jefferies LLC, Wells Fargo Securities, J.P. Morgan Securities, Citigroup Global Markets and others, per the docket).
 January 29, 2026 to May 11, 2026 October 26, 2026 or October 30, 2026
Most notices state October 30, 2026; one notice (apparent copy error) states October 26, 2026.
 D. Colo.
1:26-cv-04074		 Ask about this
Hyliion Holdings Corp. NYSE: HYLN
The complaint alleges that, to cause rapid price appreciation, defendants announced a deal with VFG Holdings, an entity that was very recently formed and did not appear to have actual business operations, and timed the announcement and resulting price rise to insider trading. The complaint alleges that after a June 23, 2026 research report questioned VFG's substance, the stock fell from $7.37 on June 22 to $4.92 on June 24, 2026, a two-day decline of $2.45, or 33.24%.
 May 12, 2026 to June 23, 2026 October 27, 2026
 W.D. Tex.
1:26-cv-02369		 Ask about this
Innventure, Inc. NASDAQ: INV
The complaint alleges that defendants misrepresented the viability of Accelsius' DarkNX data center deployment agreement and overstated Innventure's 2026 revenue and cash flow targets. The complaint alleges that the stock fell $0.54, or 8.42%, to $5.87 on May 28, 2026 after a Morpheus Research report questioned whether the DarkNX project existed, and fell $1.98, or 55%, from $3.60 to $1.62 on August 14, 2026 after Innventure suspended its 2026 revenue targets and disclosed removal of DarkNX from internal bookings.
 November 17, 2025 to August 13, 2026 October 27, 2026
 S.D.N.Y.
1:26-cv-07377		 Ask about this
XTI Aerospace, Inc. NASDAQ: XTIA
The complaint alleges that defendants failed to disclose that senior executives had engaged in undisclosed activities requiring Board review, that the company's disclosure controls were ineffective, and that it would be unable to timely file its periodic reports. The complaint alleges that on August 17, 2026 XTI disclosed it could not timely file its Form 10-Q, citing an internal review of its former CEO, who resigned that day, and the stock fell $0.25, or 15.9%, to close at $1.32 on August 18, 2026.
 April 15, 2026 to August 17, 2026 October 27, 2026
 S.D.N.Y.
1:26-cv-07378		 Ask about this
Hims & Hers Health, Inc. NYSE: HIMS
The complaint alleges that defendants failed to disclose that Hims & Hers shared consumers' health information with third-party advertising platforms and charged consumers for prescriptions almost immediately after they submitted an intake form despite representations about provider consultation, exposing the company to regulatory action and penalties. The complaint alleges that on July 29, 2026 the Federal Trade Commission filed a lawsuit against the company, and the stock fell $4.32, or 14.73%, to close at $25.00 per share.
 August 4, 2025 to July 29, 2026 November 1, 2026 or November 2, 2026
Most notices state November 2, 2026; one notice states November 1, 2026 (a Sunday).
 N.D. Cal.
5:26-cv-09313		 Ask about this
Papa John's International, Inc. NASDAQ: PZZA
The complaint alleges that defendants made materially false and misleading statements about Papa John's transformation, concealing that it was taking longer than expected, was not preventing market-share losses and would require a sharp increase in promotional efforts. The complaint alleges that on August 6, 2026 the company reported an 8.3% decline in North American comparable sales and reduced its fiscal 2026 outlook, and the stock fell $5.11, or 17.18%, to close at $24.64 per share.
 August 7, 2025 to August 5, 2026 November 2, 2026
 W.D. Ky.
3:26-cv-00685		 Ask about this
Unicycive Therapeutics, Inc. NASDAQ: UNCY
The complaint alleges that defendants failed to disclose that Unicycive had not inspected or audited its third-party manufacturing vendor's facility for compliance with current good manufacturing practices, and so lacked a reasonable basis to believe the vendor had resolved FDA-cited deficiencies, making a delay in approval of oxylanthanum carbonate (OLC) reasonably foreseeable. The complaint alleges that on June 30, 2026 the company announced an FDA Complete Response Letter, and the stock fell $3.01, or 39.1%, to close at $4.69 per share.
 December 29, 2025 to June 29, 2026 November 2, 2026
 N.D. Cal.
3:26-cv-09559		 Ask about this
Beta Bionics, Inc. NASDAQ: BBNX
The complaint alleges that defendants characterized an FDA Form 483 concerning the iLet Bionic Pancreas as raising only minor issues while concealing that the FDA had identified significant quality-management-system deficiencies and that customer complaints included serious injuries and hypoglycemic events. The complaint alleges that the stock dropped 37% on January 8, 2026 after an unexpected miss on new iLet patient starts, and declined further after the company disclosed an FDA warning letter on January 30, 2026 and the FDA publicly released it on February 24, 2026.
 July 30, 2025 to February 24, 2026 November 3, 2026
 C.D. Cal.
2:26-cv-09999		 Ask about this
Celsius Holdings, Inc. NASDAQ: CELH
The complaint alleges that defendants failed to adequately disclose cardiac and other health risks associated with Alani Nu products, including marketing to consumers under 18, and the resulting risk of adverse health events and harm to the business. The complaint alleges that the stock fell $1.52, or 4.18%, to $34.86 on April 10, 2026 after reports of a wrongful-death lawsuit involving a 17-year-old, and fell $2.26, or 7.53%, to $27.75 on June 4, 2026 after the Texas Attorney General announced an investigation.
 February 21, 2025 to June 3, 2026 November 3, 2026
 S.D. Fla.
0:26-cv-62465		 Ask about this
DICK'S Sporting Goods, Inc. NYSE: DKS
The complaint alleges that defendants failed to disclose that Foot Locker, acquired by DICK'S, remained saddled with unproductive and stagnant legacy footwear inventory and that the business faced intensifying industry-wide promotional pressure, undermining its sales and profit targets. The complaint alleges that on August 25, 2026 DICK'S reported Foot Locker revenue of $1.73 billion versus analyst estimates of $1.81 billion and cut its comparable-sales guidance to negative 2.0% to 0.0% from growth of 1.5% to 3%, and the stock fell approximately 30%.
 September 8, 2025 to August 24, 2026 November 3, 2026
 W.D. Pa.
2:26-cv-01860		 Ask about this
The ODP Corporation NASDAQ: ODP
The complaint alleges that ODP and its directors violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 in connection with ODP's acquisition by Atlas Holdings LLC, which the notice describes as being at an unfair price. The complaint alleges these claims on behalf of shareholders who held ODP common stock as of October 21, 2025 and through December 10, 2025.
Who may be affected: Merger-vote holders: the class is individuals and entities that held ODP common stock as of October 21, 2025 and kept holding through December 10, 2025. The Justia docket lists ODP and eight former directors as defendants; Atlas Holdings is not listed as a defendant on the docket.
 See case description November 3, 2026
 S.D. Fla.
9:26-cv-81028		 Ask about this
Ryde Group Ltd. NYSE American: RYDE
The complaint alleges that defendants carried out a pump-and-dump scheme in which social-media impersonators posing as financial advisors promoted Ryde shares, which rose from the $4.00 IPO price to an all-time high of $22.49 without fundamental justification, and failed to disclose the fraudulent promotion and insider share dumping. The complaint alleges that on September 11, 2024 the share price abruptly fell approximately 75%, to $5.50.
Who may be affected: Defendants other than the issuer: auditor Kreit & Chiu CPA, LLP, underwriter Maxim Group, LLC and agent Puglisi & Associates, Inc., in addition to six Ryde executives.
 March 6, 2024 to September 11, 2024 November 9, 2026
 S.D.N.Y.
1:26-cv-07854		 Ask about this
Lead plaintiff deadline passed (18)

Investors who bought during these class periods may still be class members; the passed deadline affects only who can seek appointment as lead plaintiff.

  • ADMA Biologics, Inc. (ADMA), class period August 9, 2024 to March 25, 2026. Reported deadline August 10, 2026.
  • Erasca, Inc. (ERAS), class period January 14, 2025 to April 26, 2026. Reported deadline August 10, 2026.
  • Via Transportation, Inc. (VIA). Reported deadline August 10, 2026.
  • Zillow Group, Inc. (Z), class period February 11, 2025 to May 7, 2026. Reported deadline August 10, 2026.
  • Microsoft Corporation (MSFT), class period May 1, 2025 to January 28, 2026. Reported deadline August 11, 2026.
  • Nano-X Imaging Ltd. (NNOX), class period March 31, 2025 to April 17, 2026. Reported deadline August 11, 2026.
  • Black Rock Coffee Bar, Inc. (BRCB), class period September 12, 2025 to May 12, 2026. Reported deadline August 17, 2026.
  • Embecta Corp. (EMBC). Reported deadline August 17, 2026.
  • First Solar Inc. (FSLR), class period February 26, 2025 to February 24, 2026. Reported deadline August 24, 2026.
  • Peabody Energy Corporation (BTU), class period October 14, 2024 to May 4, 2026. Reported deadline August 24, 2026.
  • ZoomInfo Technologies Inc. (GTM), class period November 3, 2025 to May 11, 2026. Reported deadline August 24, 2026.
  • Futu Holdings Ltd. (FUTU), class period May 24, 2023 to May 27, 2026. Reported deadline August 25, 2026.
  • Genius Group Limited (GNS), class period April 12, 2022 to May 30, 2025. Reported deadline August 28, 2026.
  • Hub Group, Inc. (HUBG), class period April 28, 2023 to May 11, 2026. Reported deadline August 28, 2026.
  • Insulet Corporation (PODD), class period February 21, 2025 to May 26, 2026. Reported deadline August 31, 2026.
  • Photronics, Inc. (PLAB), class period December 10, 2025 to May 27, 2026. Reported deadline September 4, 2026.
  • Intuit Inc. (INTU), class period August 22, 2025 to May 20, 2026. Reported deadline September 8, 2026.
  • Megan Holdings Limited (MGN), class period September 26, 2025 to March 25, 2026. Reported deadline September 8, 2026.

Mass torts

Open to new filings

Depo-Provera (meningioma)

MDL 3140 · U.S. District Court for the Northern District of Florida

A Master Settlement Agreement with Pfizer covering a majority of MDL and New York state-court claims was signed in July 2026. CMO 14 (Aug. 10, 2026) set a Nov. 30, 2026 settlement-registration deadline and procedures for non-settling and future-filed plaintiffs. A Rule 702 hearing is set for Sept. 18, 2026 and an initial bellwether trial for Dec. 7, 2026, subject to pending rulings. About 6,400 actions pending (JPML, Sept. 1, 2026).

Depo-Provera remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

GLP-1 drugs: Ozempic, Wegovy, Mounjaro and others (gastroparesis and GI injuries)

MDL 3094 · U.S. District Court for the Eastern District of Pennsylvania

On Aug. 15, 2025 the court ruled that plaintiffs alleging drug-induced gastroparesis must have had a gastric emptying study at the time of diagnosis. A Rule 702 evidentiary hearing is scheduled for Sept. 14-18, 2026. About 4,000 actions pending (JPML, Sept. 1, 2026); no bellwether trial date set.

Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro remain approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

GLP-1 drugs (NAION vision loss)

MDL 3163 · U.S. District Court for the Eastern District of Pennsylvania

A separate MDL for non-arteritic anterior ischemic optic neuropathy (NAION) claims. CMO 12 (July 2, 2026) front-loaded discovery on general causation and preemption, with motions expected to be fully briefed in 2027. About 216 actions pending (JPML, Sept. 1, 2026).

Ozempic, Wegovy, Saxenda and Trulicity remain approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

Chemical hair relaxers and straighteners (uterine and other cancers)

MDL 3060 · U.S. District Court for the Northern District of Illinois

About 12,100 actions pending (JPML, Sept. 1, 2026). CMO 23 (May 7, 2026) says trial schedules will be forthcoming; no bellwether date confirmed. CMO 24 (Aug. 27, 2026) set discovery for second-wave defendants through July 15, 2027. Most claims against L'Oreal, Revlon and others survived a November 2023 pleadings ruling.

Ask about this
Open to new filings

AFFF firefighting foam / PFAS exposure (cancers and other diseases)

MDL 2873 · U.S. District Court for the District of South Carolina

The court prioritized kidney cancer, testicular cancer, ulcerative colitis, thyroid disease, liver cancer and thyroid cancer (CMO 35, Aug. 15, 2025) and vacated the first injury bellwether. Rule 702 briefing in thyroid- and liver-cancer cases runs into January 2027 (CMO 33F). About 15,260 actions pending (JPML, Sept. 1, 2026).

Ask about this
Open to new filings

Bard implanted port catheters (PowerPort)

MDL 3081 · U.S. District Court for the District of Arizona

In the first bellwether (an infection case) a jury returned a defense verdict on failure to warn in May 2026 and deadlocked on design defect. On Sept. 4, 2026 a jury in the second bellwether (a catheter fracture case) found for the plaintiff on design defect and failure to warn. Six bellwether trials were approved through December 2026. About 3,700 actions pending.

Bard implanted port products remain cleared by the U.S. Food and Drug Administration for sale. Certain product lots have been recalled; the FDA recall database lists specific products.

Ask about this
Open to new filings

AngioDynamics implanted port catheters

MDL 3125 · U.S. District Court for the Southern District of California

A bellwether protocol covers infection, fracture and thrombosis cases, with expert discovery in 2027 and Rule 702 motions due Sept. 30, 2027; first trials are not expected before mid-2028. About 430 actions pending.

AngioDynamics implanted port products remain cleared by the U.S. Food and Drug Administration for sale. Certain product lots have been recalled; the FDA recall database lists specific products.

Ask about this
Open to new filings

Covidien (Medtronic) hernia mesh

MDL 3029 · U.S. District Court for the District of Massachusetts

On Aug. 4, 2026 a jury in the first bellwether returned a verdict for the plaintiff; on Aug. 19, 2026 the judge indicated she would likely reduce it and encouraged settlement talks. About 2,450 actions pending.

Certain Covidien hernia mesh products have been recalled, including a 2023 recall of a Parietex composite mesh product; other Covidien mesh products remain cleared by the U.S. Food and Drug Administration for sale.

Ask about this
Open to new filings

Paragard copper IUD (breakage on removal)

MDL 2974 · U.S. District Court for the Northern District of Georgia

Bellwether trials were scheduled for January, March and May 2026; outcomes are not confirmed in court sources reviewed. In February 2025 the court held for the states analyzed that the injury accrues at removal and dismissed some claims under limitation and repose statutes. About 4,190 actions pending.

Paragard remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

Suboxone film (dental injuries)

MDL 3092 · U.S. District Court for the Northern District of Ohio

Core discovery is underway, with trial-pool selection in January 2027 and a first trial setting in March 2028. About 1,830 actions pending, many through joinder complaints.

Suboxone sublingual film remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

Dupixent (cutaneous T-cell lymphoma)

MDL 3180 · U.S. District Court for the District of New Jersey

Centralized in the District of New Jersey in June 2026; early organizational stage with about 35 actions pending.

Dupixent remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

3M Bair Hugger forced-air warming (surgical infections)

MDL 2666 · U.S. District Court for the District of Minnesota

About 8,430 actions pending and new filings continue (JPML, Sept. 1, 2026). Reports of a 2026 bellwether and appeal are unverified in court sources.

The 3M Bair Hugger warming system remains cleared by the U.S. Food and Drug Administration for sale; certain accessories were recalled in the past.

Ask about this
Open to new filings

Cartiva synthetic cartilage implant (big toe)

MDL 3172 · U.S. District Court for the Eastern District of Arkansas

Centralized in February 2026 in the Eastern District of Arkansas; proceedings were stayed pending organization, with an organizational meeting held Aug. 26, 2026. About 21 actions pending.

Cartiva, Inc. initiated a recall of the Cartiva Synthetic Cartilage Implant on Oct. 31, 2024 (FDA recall event 95661), citing a higher than expected rate of revision, removal and other hazards.

Ask about this
Handled by a person

Social media adolescent addiction

MDL 3047 · U.S. District Court for the Northern District of California

A Los Angeles jury found Meta and Google/YouTube negligent in the first coordinated state bellwether (March 25, 2026). On Aug. 26, 2026 the MDL court approved Meta's settlement with state attorneys general, which does not resolve individual injury suits. About 3,200 actions pending.

Ask about this
Handled by a person

Preterm infant formula (necrotizing enterocolitis, NEC)

MDL 3026 · U.S. District Court for the Northern District of Illinois

Abbott announced on Aug. 20, 2026 an agreement to settle about 2,000 claims; many others remain. Mead Johnson won the first MDL bellwether on Aug. 31, 2026. About 850 MDL actions pending, with thousands more in state courts.

Ask about this
Handled by a person

Rideshare passenger sexual assault (Uber, Lyft)

MDL 3084 (Uber); MDL 3171 (Lyft) · U.S. District Court for the Northern District of California

Juries found Uber liable in two 2026 federal bellwether trials; further bellwethers were scheduled from mid-September 2026. Lyft cases are centralized separately (MDL 3171). About 4,600 Uber actions pending.

Ask about this
Handled by a person

Roblox and Discord child sexual exploitation

MDL 3166 · U.S. District Court for the Northern District of California

Motions to compel arbitration and to dismiss are being briefed; the court gave notice in April 2026 of its intent to appoint a settlement master. About 180 actions pending.

Ask about this
Handled by a person

ByHeart infant formula (infant botulism)

MDL 3178 · U.S. District Court for the Southern District of New York

ByHeart recalled all of its infant formula nationwide on Nov. 11, 2025 after an infant botulism outbreak (FDA and CDC). The MDL is at an early stage with about 22 actions pending.

Ask about this
Closed to new claims or materially limited (17)
  • Philips CPAP / BiPAP / ventilator recall (MDL 3014). The personal-injury Master Settlement Agreement was entered May 9, 2024; under the court's same-day Docket Management Order, claimants who did not register by the settlement's Registration Deadline, and anyone filing later, must produce medical records and device-use proof within 60 days and causation expert reports within 90 days or face dismissal with prejudice.
  • 3M Combat Arms earplugs (MDL 2885). 3M's settlement of Combat Arms earplug claims was announced Aug. 29, 2023, with eligible claimants identified as of a Sept. 12, 2023 reference date and awards paid through the settlement administrators; litigants who declined the settlement remain subject to CMO 57's litigation requirements.
  • Zantac / ranitidine (federal MDL 2924). Judge Robin Rosenberg excluded plaintiffs' general-causation experts in December 2022; plaintiffs' Eleventh Circuit appeal was argued Oct. 10, 2025, and its outcome is unverified as of September 2026.
  • Zantac / ranitidine (Delaware state court). In July 2025 the Delaware Supreme Court reversed the Superior Court ruling that had allowed plaintiffs' expert testimony (342 A.3d 1131), returning the cases for expert review under the corrected standard; GSK had separately agreed to settle roughly 80,000 state-court claims.
  • Roundup: failure-to-warn claims (Monsanto Co. v. Durnell). On June 25, 2026, the U.S. Supreme Court held 7-2 that FIFRA expressly preempts a state-law failure-to-warn claim that would require a cancer warning on Roundup's label, reversing and remanding the Missouri judgment.
  • Roundup: proposed nationwide NHL class settlement (King v. Monsanto, Missouri state court). The opt-out deadline for the proposed class settlement of current and future Roundup non-Hodgkin lymphoma claims passed June 4, 2026, and the fairness hearing is set for Sept. 14, 2026; class members diagnosed after March 4, 2026 may apply within six years of diagnosis if the settlement becomes final.
  • Johnson & Johnson talc (ovarian cancer; MDL 2738 and related state cases). On July 22, 2026, the MDL court ordered plaintiffs to show why remaining ovarian-cancer talc claims should not be dismissed for lack of specific-causation proof, and on July 27, 2026, J&J announced a proposed resolution of about 76,000 existing ovarian talc claims, conditioned on 95% participation and excluding mesothelioma claims.
  • Paraquat (MDL 3004). Syngenta and Chevron executed a Master Settlement Agreement with plaintiffs' leadership on Aug. 4, 2025, and CMO 25 (June 12, 2026) imposes Lone Pine-type requirements, including a case-specific causation expert report and a Parkinson's diagnosis by a neurologist or movement-disorder specialist, on non-settling, ineligible and newly filed plaintiffs.
  • Camp Lejeune Justice Act. The Department of the Navy states that the CLJA filing deadline passed on Aug. 10, 2024 and that it is no longer accepting new CLJA claims; claims filed by the deadline remain under review.
  • Acetaminophen / Tylenol autism-ADHD (MDL 3043). Judge Denise Cote granted defendants' motions to exclude plaintiffs' expert opinions on Dec. 18, 2023 and July 10, 2024, and the court's MDL page lists no later orders.
  • Exactech orthopedic implants (MDL 3044). Exactech filed Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on Oct. 29, 2024; the general claims bar date was Feb. 7, 2025, and the plan was confirmed Sept. 17, 2025 and became effective Oct. 31, 2025.
  • Hernia mesh: Davol/C.R. Bard polypropylene mesh (MDL 2846). CMO 55 (Nov. 21, 2024) appointed special masters and set an Intensive Settlement Process for opt-out and other non-settling claimants beginning on or about Jan. 4, 2027, with cases filed after the Docket Control Orders eligible only if Administering Counsel and Bard agree.
  • Hernia mesh: Ethicon Physiomesh (MDL 2782). The JPML's Sept. 1, 2026 report lists no pending actions in MDL 2782 (4,054 total actions).
  • Taxotere / docetaxel (MDL 2740). The JPML's Sept. 1, 2026 report lists 81 pending of 15,572 total actions in MDL 2740 (hair loss) and 140 pending of 433 in the separate eye-injury MDL 3023.
  • Gardasil (MDL 3036). The Fourth Circuit on Sept. 4, 2025 affirmed dismissal of three bellwether cases on Vaccine Act timeliness grounds, and only 6 of 258 actions remained pending in MDL 3036 as of September 2026.
  • Juul (MDL 2913). The JPML's Sept. 1, 2026 report lists 11 pending of 7,071 total actions in MDL 2913.
  • Baby food heavy metals, autism/ADHD (MDL 3101). On Aug. 13, 2026, Judge Jacqueline Scott Corley indicated she would grant summary judgment against a substantial portion of the MDL's ADHD and autism claims, following her earlier ruling that plaintiffs' causation evidence was unreliable.

Do not see your case? If a company, product, or practice that affected you is not listed, tell the firm anyway. Many matters begin that way. Case evaluation.

Schwartz & Associates, PC is responsible for the content of this website. Responsible attorney: Lou Schwartz, Esq. The firm may refer matters to, or handle them together with, other lawyers.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment.

Compiled Sept. 11, 2026 from JPML pending-MDL statistics (Sept. 1, 2026), MDL court orders and pages, FDA/CDC notices, openFDA recall records and reputable legal press. Status can change quickly; confirm before relying.

If something happened to more people than you, tell us.

Many class actions begin with one person who noticed a pattern. Reviewing your information costs nothing and creates no obligation.

Case Evaluationor call (918) 238-6445